2026
Element Eleven Facilitates Medical AI–AHA Collaboration
Element Eleven facilitated a collaboration between Medical AI and the American Heart Association (AHA) to establish a 20-site cluster-randomised study in the United States as part of an implementation science programme.
The collaboration was further advanced at ESC Congress 2026, where a formal meeting was held between Medical AI leadership and AHA leadership.
Medical AI and AHA leadership meeting at ESC Congress 2026.
HighTide Research Presented in Advances in Science Session at ESC Congress 2026
Filip Surmont presented HighTide Therapeutics' latest clinical research at ESC Congress 2026 in Munich, with an oral presentation in the Advances in Science session.
The presentation highlighted Phase 3 SYMPHONY trial data evaluating HTD1801 as a multisystem cardio-kidney-metabolic therapy in people with type 2 diabetes.
Filip Surmont presenting at ESC Congress 2026 in Munich.
Filip Surmont Presents at the Peking University Diabetes Forum
Filip Surmont presented at the 22nd Peking University Diabetes Forum in Beijing, one of China's leading academic conferences in diabetes and a major forum for diabetes prevention and research.
Sharing HighTide Therapeutics' work with leading experts in diabetes. During the meeting, Filip joined Professor Ji Linong, Chairman of the Peking University Diabetes Forum and one of China's leading diabetes experts.
Filip Surmont with Professor Ji Linong, Chairman of the Peking University Diabetes Forum.
HighTide Research Selected for Focused Oral Presentation at ERA Congress 2026
HighTide Therapeutics research was selected for a focused oral presentation at the 63rd ERA Congress in Glasgow. The research explored the potential renoprotective effects of HTD1801, including its effects on podocyte inflammation, apoptosis and glomerular injury.
The work, HTD1801 Attenuates Podocyte Apoptosis and Glomerular Injury: Mechanistic Insights into Renoprotection, included Filip Surmont as an author.
HTD1801 research presented at the 63rd ERA Congress, Glasgow.
HighTide Weight-Loss Research Presented at ADA 2026
HighTide Therapeutics research was accepted for presentation at the American Diabetes Association's 2026 Scientific Sessions. The research explored HTD1801 in combination with GLP-1 receptor agonists, including its potential to enhance weight loss and reduce weight rebound following GLP-1RA discontinuation.
The supplied abstract specifically covers HTD1801 in combination with semaglutide and tirzepatide and examines weight loss, body composition and rebound following semaglutide withdrawal.
Enhanced weight loss with HTD1801 in combination with GLP-1RAs in DIO mice.
HighTide Research Accepted for ASN Kidney Week 2026
HighTide Therapeutics research has been accepted for presentation at ASN Kidney Week 2026, further advancing the scientific programme evaluating HTD1801 in kidney disease.
The accepted work examines the effects of HTD1801 on cyst expansion in PKD1-mutant nephron organoids and the AMPK–NLRP3 axis.
HighTide Therapeutics Presented During J.P. Morgan Week 2026
Filip Surmont presented HighTide Therapeutics' clinical development programme in San Francisco during J.P. Morgan Week 2026, highlighting the company's pipeline of novel therapies targeting cardio-kidney-metabolic disease.
Filip Surmont presenting HighTide Therapeutics' clinical development programme in San Francisco.
Filip Surmont Appointed Chief Medical Officer of HighTide Therapeutics
In March 2026, Dr. Filip Surmont, founder of Element Eleven, has been appointed Chief Medical Officer of HighTide Therapeutics, a global biopharmaceutical company advancing innovative therapies for cardiovascular-kidney-metabolic (CKM) diseases.
In this role, Filip will lead the company’s global medical strategy, clinical development, and medical affairs, supporting the continued advancement of HighTide’s pipeline addressing major unmet needs in chronic metabolic disease.
Filip brings more than three decades of experience across clinical practice and the pharmaceutical industry, including senior leadership positions at Wyeth, Pfizer, and AstraZeneca. Throughout his career, he has helped shape global medical strategy in cardiovascular, renal, and metabolic medicine, contributing to major therapeutic and guideline-level advances impacting millions of patients worldwide.
Alongside this appointment, Filip continues to lead Element Eleven, where he advises life-science organisations on medical strategy, global medical affairs, and real-world evidence.
Since joining the Scientific Advisory Board, Filip has been formally inducted as a board member and the first iCTS Clinical Trial Skills Course has been successfully delivered. A second course is now in development.
2025
HighTide Late-Breaking Research Presented at CVCT 2025
Filip Surmont presented HighTide Therapeutics research at CVCT 2025, including a late-breaking oral presentation on kidney protection with HTD1801 and a DCRI session presentation exploring its potential in cardiovascular-kidney-metabolic disease and heart failure prevention.
Filip Surmont presenting at CVCT 2025
.png)
Work by Element Eleven and Filip Surmont led to a Late-Breaking Poster presentation at the American Society of Nephrology (ASN) Kidney Week 2025, showcasing novel evidence of kidney benefit with HTD1801.
PRESS RELEASE:
Filip Surmont formally inducted to iCTS Scientific Advisory Board
In October 2025 Filip Surmont was invited to serve as a Board Member of iCTS (Intelligent Clinical Trials Solutions), a pioneering organisation tackling the shortage of quality Clinical Trials Management in high-need communities through innovative CTM services.
Following his appointment to the iCTS Scientific Advisory Board, Filip Surmont has now been formally inducted as a board member. The first iCTS Clinical Trial Skills Course has also been successfully delivered, with a second course now in development.
Filip Surmont’s work with Element Eleven contributed to a Late-Breaking Clinical Trial presented at the European Society of Cardiology Heart Failure Congress 2025, showcasing an AI-enabled ECG algorithm for detecting heart failure across nearly 6,000 adults in Kenya — advancing accessible, data-driven healthcare innovation in low-resource settings.